CERo Therapeutics Holdings, Inc. Warrants (CEROW)

• Market cap: $2.87M
• 1 day: 0.85%
• 5 days: 4.39%
• 1 month: -30.00%
• 3 months: -21.71%
• 6 months: -50.21%
• Year to date: 19.00%
• 1 year: -79.30%
• 5 years: -97.71%
• 10 years: -97.71%
• Sector: Healthcare
• Industry: Biotechnology

About: CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Employees: 8

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more capital invested

Capital invested by funds: $28.6K [Q4 2024] → $45.7K (+$17.1K) [Q1 2025]

0.12% more ownership

Funds ownership: 2.13% [Q4 2024] → 2.26% (+0.12%) [Q1 2025]

0% more funds holding

Funds holding: 26 [Q4 2024] → 26 (+0) [Q1 2025]

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 3